PTCT insider activity: 10,000 share buy, multiple sales under 10b5-1 plan
Rhea-AI Filing Summary
PTC Therapeutics director Emma Reeve reported multiple transactions on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/04/2025. The filings show a mix of purchases and sales in the issuer's common stock and related stock options. Across the trades on that date the reporting person acquired 10,000 shares and additional option grants totaling 25,562 option rights at exercise prices of $33.02 and $33.63, while executing several sales at weighted average prices in the mid-$60s. The director's reported direct beneficial ownership after the transactions is 10,332 shares.
The transactions were effected pursuant to the 10b5-1 plan and several sale prices are disclosed as weighted averages across multiple trades; detailed per-trade price breakdowns are offered on request to regulators or the issuer.
Positive
- Transactions executed under a written Rule 10b5-1 plan adopted on 03/04/2025, providing structured timing for trades
- Acquisition of option rights totaling 25,562 (10,000; 6,912; 8,650) with exercise prices at $33.02 and $33.63, which may align incentives with long-term value
Negative
- Material net reduction in direct common-stock holdings to 10,332 shares after multiple sales on 10/03/2025
- Multiple dispositions executed at weighted average prices in the mid-$60 range, indicating significant share sales the same day options were recorded
Insights
TL;DR: A director used a 10b5-1 plan to execute mixed purchases, option activity and multiple stock sales on 10/03/2025.
The pattern shows a director-initiated trading program with both acquisitions and dispositions recorded the same day. The report discloses option rights with exercise prices at $33.02 and $33.63, and common-stock sales executed at weighted average prices in the mid-$60 range. Using a pre-established plan is a standard governance practice to create an affirmative defense under trading rules.
Key dependencies and near-term items to watch include any additional filings amending these transactions and whether the issuer or the director discloses further plan details; the plan adoption date of 03/04/2025 is the monitorable milestone that supports the defense.
TL;DR: The filing records option grants/exercises and purchases that increase option exposure while common shares were sold.
The derivative table shows acquisition of option rights totaling 25,562 option units (10,000 + 6,912 + 8,650) exercisable immediately at the stated prices and currently exercisable. However, the reported number of shares beneficially owned directly after the transactions is reduced to 10,332, reflecting net dispositions in common stock executed the same day. Option strike prices are $33.02 and $33.63, significantly below the sale prices reported.
Monitor whether options are exercised or converted into shares in subsequent filings and any schedule changes around option vesting or additional 10b5-1 plan activity in the coming months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 6,912 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 8,650 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $39.42 | $394K |
| Sale | Common Stock | 3,028 | $65.09 | $197K |
| Sale | Common Stock | 4,591 | $66.09 | $303K |
| Sale | Common Stock | 2,381 | $66.87 | $159K |
| Exercise | Common Stock | 6,912 | $33.02 | $228K |
| Sale | Common Stock | 2,163 | $65.02 | $141K |
| Sale | Common Stock | 3,149 | $66.11 | $208K |
| Sale | Common Stock | 1,600 | $66.93 | $107K |
| Exercise | Common Stock | 8,650 | $33.63 | $291K |
| Sale | Common Stock | 2,729 | $65.05 | $178K |
| Sale | Common Stock | 4,037 | $66.10 | $267K |
| Sale | Common Stock | 1,884 | $66.89 | $126K |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.50 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.46 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable.
